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Objective: Little is known about initial prescription of currently used oral anticoagulants
(OAC), and correlated characteristics in real-world practice. We aimed to assess patterns
of initiation of Vitamin K antagonists (VKA) and non-VKA oral anticoagulants (NOAC) in
naive patients with non-valvular atrial fibrillation and the factors associated with starting
treatment with NOAC.
Methods: Population-based retrospective cohort study of all patients with NVAF who
had a first prescription of OAC from November 2011 to February 2014 in the Valencia
region, Spain (n= 21,881). Temporal trends of OAC initiation are described for the whole
population and by type of OAC and therapeutic agent. Factors associated with starting
treatment with NOAC (vs. VKA) were identified using logistic multivariate regression
models.
Results: Among the patients initiating OAC, 25% started with NOAC 2 years after
market release. Regarding temporal trends, prescription of NOAC doubled during the
study period. VKA prescription also increased (by around 13%), resulting in a 30% rise
in total treatment initiation with OAC during 2011–2014. NOAC initiation (vs. VKA) was
associated with a lower baseline risk of thromboembolism and higher income.
Conclusions: In this Spanish population-based cohort, initiation of OAC therapy saw a
rapid increase, mainly but not exclusively, due to a two-fold rise in the use of NOAC.
Initiation with NOAC was associated with a lower baseline risk of thromboembolism
and higher income, which opposes the indications of NOAC use and reflects disparities
in care. Inadequate prescription patterns might threaten the effectiveness and safety
of these therapies, thus monitoring OAC prescription is necessary and should be
setting-specific.
Keywords: anticoagulants, atrial fibrillation, stroke prevention, pharmacoepidemiology, drug prescription, real-
world data, non-VKA oral anticoagulants
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INTRODUCTION
Drug prescription to naïve patients—initial prescription—is
the starting point for establishing treatment adequately, and
provides an important opportunity to engage patients in
therapy. Oral anticoagulation (OAC) significantly reduces the
risk of stroke in patients with atrial fibrillation when used
adequately (1990; 1991; 1994; Petersen et al., 1989; Lancaster
et al., 1991). Vitamin K antagonists (VKA) (Fuster et al.,
2012; January et al., 2014), and more recently the non-VKA
oral anticoagulants (NOAC), which are comparable in efficacy
and safety to VKA (Connolly et al., 2009; Granger et al.,
2011; Patel et al., 2011), are the therapy indicated for this
purpose. NOAC have some theoretical advantages over VKA
such as the scarcity of interactions, predictable effects with
fixed dosages and no need for monitoring. Nevertheless, they
also have significant limitations, including the unavailability of
FIGURE 1 | Eligibility and exclusion criteria to define the study cohort. Patients served by the Valencia Health System. Spain.
tests for monitoring their anticoagulant effectiveness, the low
availability of antidotes to reverse their effect, and renal clearance.
Additionally, their cost far outweighs that of traditional
anticoagulation.
Consequently, diverse guidelines recommend the use of
NOAC or VKA to reduce the risk of stroke, although
different approaches are being used. For example, US guidelines
recommend the use of either NOAC or VKA for the prevention
of stroke (Wann et al., 2011). NOAC as first line therapy is
recommended by European guidelines (Camm et al., 2010, 2012)
whereas in Spain, the prescription of NOAC in patients with
AF requires prior authorization (AEMPS, 2016). However, very
little is known about anticoagulant therapy use or initiation
globally. Two recent studies, one set in China—registry-based-
and the other in Denmark—population-based-, explored oral
anticoagulant use, but not initiation in naïve patients (Adelborg
et al., 2016; Chang et al., 2016).
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Evidence on initial prescription patterns and their predictors
for direct and traditional oral anticoagulants in patients with
non-valvular atrial fibrillation, comes from one study in the
United States (Desai et al., 2014) and another in Denmark
(Olesen et al., 2015), only the latter being population-based.
The current—and ongoing—assessment of initiation patterns
and factors related to them might provide useful insights into
the appropriateness of initial prescription according to approved
indications, as well as data that can be used for posterior
surveillance or to study adequately comparative effectiveness in
real world practice.
To address this global knowledge gap, we aimed to describe
the patterns of prescription of oral anticoagulants (VKA and
NOAC) as a starting treatment in naïve patients with non-
valvular atrial fibrillation, and to study factors associated with




Population-based retrospective cohort study of all patients with
atrial fibrillation, who were prescribed oral anticoagulant therapy
from November 2011 (date of marketing of first NOAC in Spain)
to February 2014 in the Valencia region.
Population and Setting
The study was set in the Valencia region and, specifically,
in the population covered by the Valencia Health System
(VHS), the public health system covering about 97% of
the region’s population (≈5 million inhabitants). All patients
with AF (diagnosis code of International Classification of
Diseases, 9th Revision, Clinical Modification [ICD-9-CM]
427.31) newly prescribed with oral anticoagulants (warfarin,
acenocoumarol, dabigatran, rivaroxaban, apixaban) for the
prevention of thromboembolic events between November 2011
and February 2014 were included. We defined as naïve
those patients without anticoagulant treatment in the 12
months preceding the index date (first prescription). People
without pharmaceutical/health coverage by VHS, mainly certain
government employees whose prescriptions are reimbursed
by civil service insurance mutualities, and thus not included
in the pharmacy databases of the VHS, and patients not
registered in the municipal census (non-residents or temporary
residents), were excluded because of limitations on follow-up.
We also excluded patients with concomitant valvular heart
disease (ICD-9: 394.x-397.x, 398.9, 42.4x, V42.2, V43.3, 35.1x,
35.2x). This left a total of 21,881 patients included in the study
(Figure 1).
Data Sources
The main source of data was the VHS ambulatory electronic
medical record (EMR), the so-called ABUCASIS system, which
among other information includes demographic and clinical
data, and information on prescriptions and dispensations. The
information on hospitalizations was based on the Minimum
Basic Dataset (MBDS) at hospital discharge, a synopsis
of clinical and administrative information on all hospital
discharges, including diagnoses and procedures. VHS coverage
and some demographic characteristics were obtained from
the Population Information System. A detailed description of
the data sources is found elsewhere (Sanfélix-Gimeno et al.,
2015).
TABLE 1 | Characteristics of patients with non-valvular atrial fibrillation
starting OAC therapy, and by VKA and NOAC.
OAC VKA NOAC
N (%) 21.881 17.948 (82.03) 3.933 (17.97)
Female (%) 47.65 47.7 47.42
Age, years, mean (SD) 74.50 (10.08) 74.56 (9.86) 74.22 (11.06)
COUNTRY (%)
Spain 96.49 96.54 96.26
European 3.29 3.23 3.56
Non-European 0.22 0.23 0.18
ANNUAL INCOME, e, (%)
<18,000 83.72 84.79 78.88
18,000–100,000 15.99 14.58 20.51
>100,000 0.29 0.22 0.61
COMORBIDITIES (%)
Congestive heart failure 21.33 22.00 18.28
Hypertension 79.35 79.70 77.73
Diabetes 30.91 31.68 27.41
Liver disease 6.22 6.36 5.57
Renal disease 11.77 12.55 8.21
Previous ischemic stroke or TIA 14.47 13.96 16.83
Coronary artery disease 20.96 21.21 19.86
Deep vein thromboembolism or
pulmonary embolism
6.09 6.48 4.30
Hemorrhagic stroke 0.82 0.70 1.37
Gastrointestinal bleeding 3.66 3.69 3.51
Other major bleeding 20.60 20.84 19.48
Bleeding history or predisposition 23.19 23.35 22.48
CHADS2 score, mean (SD) 2.18 (1.25) 2.19 (1.26) 2.12 (1.34)
CHA2DS2-VASC score, mean (SD) 3.85 (1.70) 3.86 (1.70) 3.71 (1.82)
HAS-BLED score, mean (SD) 2.23 (1.00) 2.23 (1.00) 2.16 (1.03)
HEALTHCARE UTILIZATION, MEAN (SD)
Number of medications 9.89 (4.82) 9.96 (4.86) 9.57 (4.68)
Hospitalizations 0.66 (0.94) 0.68 (0.96) 0.61 (0.90)
Emergency department visits 1.22 (1.49) 1.25 (1.50) 1.07 (1.46)
Outpatient visits
Cardiologist visits 0.47 (0.85) 0.43 (0.82) 0.66 (0.98)
Neurologist visits 0.14 (0.53) 0.14 (0.51) 0.19 (0.65)
Family physician visits 10.36 (7.28) 10.37 (7.20) 10.32 (7.68)
Social work visits 0.09 (0.68) 0.09 (0.68) 0.09 (0.70)
Mental health visits 0.09 (0.84) 0.09 (0.81) 0.11 (0.96)
Nurse visits 8.54 (11.57) 8.74 (12.01) 7.65 (10.59)
Hospitalization in 30 days before
treatment initiation (%)
30.82 31.41 28.12
Retrospective cohort of naïve patients in the Valencia Region. Data presented as
percentages or means (SD). OAC indicates oral anticoagulants (both VKA and NOAC);
VKA, Vitamin K antagonists NOAC, Non-VKA oral anticoagulants; TIA, transient ischemic
attack.
Frontiers in Pharmacology | www.frontiersin.org 3 February 2017 | Volume 8 | Article 63
Rodríguez-Bernal et al. Initiation Patterns of Oral Anticoagulants
Covariates
We included patients’ sociodemographics and a wide range
of data on patients’ comorbidities, drug, and health care
utilization. Sociodemographic data included age, sex, country
of origin, and income. Information on baseline comorbidities
was obtained by taking into account the 365 days before
the index date. The following covariates were considered:
Congestive heart failure, hypertension, diabetes, liver, and
renal disease, previous ischemic stroke or TIA, coronary
artery disease, deep vein thromboembolism or pulmonary
embolism, hemorrhagic stroke, gastrointestinal bleeding, other
major bleeding and bleeding history, or predisposition. The
risk of major bleeding was measured with the HAS-BLED
score, and CHADS2 or CHA2DS2-VASc (Gage et al., 2001;
Lip et al., 2010; Pisters et al., 2010) were used to assess the
baseline risk of thromboembolic events. Regarding drug-related
variables, electronic dispensing (e-prescriptions transmitted
directly to the pharmacy) was included. Indicators of health
care utilization in the previous year were also estimated:
the number of medications, hospitalizations, emergency
department visits, visits to outpatient care (cardiologist,
neurologist), social worker, nurse and mental health.
Hospitalization 30 days before treatment initiation was also
included.
Ethics Statement
The study protocol was approved by the Clinical Research
Ethics Committee of the “Dirección General de Salud Pública”
y “Centro Superior de Investigación en Salud Pública” and
reviewed and classified by the Spanish Agency of Pharmacy and
Medical Products. Data was sent by the VHS to researchers
with dissociate non-traceable codes that would not allow the
identification of individual patients. The exemption of informed
consent was approved by the Ethics Committee considering the
characteristics of the study.
Statistical Analysis
Cohort characteristics were described according to the type
of OAC prescribed as starting treatment (VKA vs. NOAC).
Temporal trends of OAC initiation (patients starting OAC
treatment per month during the study period) were plotted
for the whole population, and according to the therapeutic
agent, as well as to the type of OAC (VKA/NOAC). Logistic
multivariable regression models were constructed to identify
predictors of anticoagulation initiation with NOAC (vs. VKA).
Backward forward stepwise methods were used to remove
nonsignificant variables (with a removal probability of 0.10
and an entry probability of 0.05). The goodness-of-fit was
evaluated using the C-Statistic (the area below the receiver
operating characteristic [ROC] curve) for discrimination and
the Hoshmer-Lemeshow test for calibration. Additionally,
we calculated the mean value of the CHADS score by
therapeutic group and for total OAC prescription along the
study period. All statistical analyses were performed using the




Our population comprised 21,881 patients, of whom 18% were
prescribed NOAC for the initiation of anticoagulation therapy,
overall (Table 1). Mean age was 74.5 years and 48% of the
population were females. Around 14% of patients had a previous
stroke, and the cohort had a mean score of 2.2 for both the
CHADS2 and HAS-BLED scores.
VKA initiators were more likely to have higher risk scores,
more comorbidities and higher health services utilization,
overall. NOAC initiators were more likely to have higher income,
previous ischemic stroke and hemorrhagic stroke, andmore visits
to cardiologist and neurologist.
Temporal Trends
Prescription rates of acenocoumarol as starting treatment
did not seem to be affected by the introduction of NOAC
(Figure 2). Concurrently, each NOAC showed a steep rise
after its introduction onto the market, leveling out afterwards.
The introduction of each new NOAC seemed to slightly
affect the market share of those already available. However,
they experienced a recovery to their initial levels, with no
apparent substitution effect among them. Apixaban seemed to
experience amoremodest increase than the previous twoNOACs
(rivaroxaban and dabigatran), although apixaban was available
for a shorter period in our study.
Temporal trends in total OAC initiation, and by therapeutic
class are shown in Figure 3. The number of patients starting
anticoagulation treatment with NOAC more than doubled
during the period of study (from 97 new patients per month
in January 2012 to 225 in January 2014). In relative terms, 2
years after the introduction onto the market of the first NOAC
(i.e., November 2013, as NOAC were released in November
2011), 25% of patients with AF starting OAC therapy were
being prescribed NOAC. The number of patients prescribed
VKA as initial treatment also increased, by around 13% (from
632 new patients per month in January 2012 to 717 in January
2014). Overall, a cumulative rather than a substitutive effect
was observed, resulting in a rise of around 30% in the total
OAC initiation rate during the study period (730 new patients
started treatment in January 2012 as compared to the 942
who did so in January 2014). Furthermore, from the total
number of patients starting OAC therapy, the percentage starting
with NOAC rose from 13.4% in January 2012 to 23.9% in
January 2014.
Predictors of OAC Initiation
In the adjusted analysis, the initiation of therapy with NOAC
was positively associated with annual income, older age (66–
75 vs. ≤ 65 years), previous stroke, intracranial hemorrhage,
and at least one visit to the cardiologist and neurologist;
patients with renal and coronary artery disease, diabetes,
deep vein thromboembolism, and at least two emergency
department visits were less likely to initiate with NOAC
(Table 2).
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FIGURE 2 | The x axis represents the months during the study period. The y axis represents the number of patients initiating OAC therapy.
DISCUSSION
In the present study, 25% of patients with AF starting OAC
therapy were being prescribed NOAC as initial treatment 2 years
after the introduction onto themarket of the first NOAC. Overall,
we found that initiation with NOAC doubled during the study
period. VKA initiation also increased (by around 13%) with no
apparent substitution effect by NOAC. Therefore, total treatment
initiation with OAC rose by a staggering 30% during the study
period. Regarding temporal trends in the initiation of NOAC,
steep rises were observed for dabigatran and rivaroxaban after
their introduction, followed by stabilization, whereas apixaban
(the last drug entering the market) seems to have had a more
modest increase (although it had a shorter observation period).
The most important predictors of NOAC initiation (vs. VKA)
were a lower baseline risk of thromboembolic events (based on
stroke risk factors) and higher income.
To our knowledge, only two studies have assessed OAC (VKA
and NOAC) initiation patterns in real-world practice to date
(Desai et al., 2014; Olesen et al., 2015). The most remarkable
finding in our population-based cohort is that, apart from the
important increase in the prescription of NOAC as starting
treatment, VKA prescription also increased, resulting in an
important rise in total treatment initiation with OAC, with no
apparent substitution effect; while the US (Desai et al., 2014)
and the Danish (Olesen et al., 2015) studies showed a decline
in rates of VKA use and a considerable uptake in NOAC,
suggesting a shift from VKA to NOAC. Approximately 2 years
after the introduction onto the market of the first NOAC, in the
US and Danish studies around 60% of patients initiating oral
anticoagulation therapy did so with NOAC, while in our study
around 24% of patients started therapy with NOAC.
These discrepant findings are likely to be due to the differences
among practice guidelines and barriers for NOAC prescription in
Spain. While the European Society of Cardiology has expressed
a preference for NOAC over VKA in stroke prevention for AF
patients (Camm et al., 2010, 2012) and the ACC/AHA/HRC
guidelines have the same level of recommendation for VKA
and NOAC (Wann et al., 2011; January et al., 2014), in Spain
NOAC are recommended as a second line treatment and their
prescription requires prior authorization.
Regarding the increase in total OAC prescription as starting
treatment, a plausible explanation is that in our population, the
threshold for OAC initiation may have decreased over time.
However, when assessing CHADS2 scores yearly and by drug,
we observed that they increased over time in both, NOAC and
VKA users (Supplementary Figure 1), suggesting that either
more high-risk patients have been treated, or that due to the
prior authorization necessary in the case of NOAC prescription,
physicians are prone to register comorbidities more accurately,
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FIGURE 3 | The x axis represents the months during the study period. The y axis represents the number of patients initiating OAC therapy.
overall. Another possible explanation is that OAC therapy has
been recently in the focus of scientific attention and marketing
strategies, resulting in a global increase in OAC prescription.
Regardless of the explanation, this, overall, probably implies a
potential improvement in care in our setting, given that in our
study the risk profile of patients treated—as measured by the
CHADS2 score-increased over time (Supplementary Figure 1),
suggesting that high-risk patients were being
under-treated.
Regarding factors related to treatment initiation with NOAC
(vs. VKA), lower rates of renal disease and higher rates of
previous hemorrhagic stroke were found in NOAC patients, as
expected. Although not directly comparable, the findings of two
previous studies are similar (Brais et al., 2015; Patel et al., 2015).
Coronary artery disease in our study was inversely associated
with NOAC initiation, probably due to controversial evidence
about higher myocardial infarction risk with dabigatran therapy
(Douxfils et al., 2014; Giglio et al., 2014). However, Patel et al.
found no association between NOAC prescription and coronary
disease (Patel et al., 2015).
Furthermore, prescription of NOAC as starting treatment was
associated overall with a lower baseline risk of thromboembolic
events (as indicated by stroke risk factors) and higher income.
These findings are supported by those of Desai et al. (2014) and
suggest an indication bias that opposes the indication of NOAC
prescription among patients with a higher risk of stroke or other
thromboembolic events, which according to the evidence will
benefit the most of the use of NOAC as compared with VKA.
This situation highlights the need to monitor the use
and appropriateness of OAC prescriptions and to study
the comparative effectiveness and safety, costs and cost-
effectiveness of OAC agents in real world clinical practice. Such
assessments will add important insights for decision-making
among stakeholders, medical professionals, and patients.
Study Strengths and Limitations
Our study has reliable data on clinical characteristics including
diagnoses and procedures, health services utilization, as well
as prescription and dispensing; and individual-level data on
sociodemographics, retrieved through the linkage of several
electronic databases including EMRs, unlike previous studies
which data is based on administrative claims. Besides, our cohort
is population based. It uses data of the population covered by
the public health system, which virtually covers the totality of
the inhabitants of the region. These are important advantages
over previous studies assessing initiation of oral anticoagulation
therapy in real world practice.
The most important limitation of our study is that
information biases due to absent registration or differing data
recording practices in the EMR might exist, although this is
an inherent problem of any study using data from routine
clinical practice. Moreover, misclassification (on exposure and
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TABLE 2 | Factors associated with NOAC initiation (vs. VKA).
OR 95% CI p-value
Age, 65–74 y (ref. < 65) 0.87 0.81–0.94 0.001
ANNUAL INCOME, e, (%)
<18,000 1 1
18,000–100,000 1.41 1.28–1.54 <0.0001
>100,000 2.63 1.55–4.46 <0.0001
COMORBIDITIES (%)
Congestive heart failure 0.91 0.83–0.99 0.039
Diabetes 0.85 0.79–0.92 <0.0001
Renal disease 0.68 0.60–0.77 <0.0001
Previous ischemic stroke or TIA 1.31 1.18–1.45 <0.0001
Coronary artery disease 0.90 0.82–0.99 0.024
Deep vein thromboembolism or
pulmonary embolism
0.71 0.60–0.83 <0.0001
Hemorrhagic stroke 1.93 1.39–2.69 <0.0001
HEALTHCARE UTILIZATION
Emergency department visits (ref. <2) 0.78 0.73–0.84 <0.0001
Ambulatory visits
Cardiologist visits 1.19 1.05–1.34 <0.0001
Neurologist visits 1.86 1.73–2.00 0.005
Retrospective cohort of naïve patients in the Valencia Region. NOAC indicates non-VKA
oral anticoagulants; VKA, Vitamin K antagonists; OR, Odds Ratio; TIA, transient ischemic
attack. Stepwise multivariable logistic regression. Only statistically significant covariates
retained in the model are presented. All covariates (as presented in Table 1) were included
in the model. Pseudo R2 = 0.03; p < 0.0001; C-Statistic: 0.62; p(x2) Hosmer-Lemeshow
= 0.3739.
covariates) is expected to be non-differential across groups of
study subjects. Additionally, when constructing the CHADS risk
score, INR was not included, given the unavailability of data
for INR values. However, it is unlikely that scores have been
affected to the extent of misclassifying patients along the score
ranges. Although relevant predictors of NOAC initiation have
been identified, the discriminatory capacity of the regression
model is low, suggesting that other non-identified factors are
driving the selection of NOAC (vs. VKA) as starting treatment.
CONCLUSIONS
NOAC prescription as initial treatment in patients with
non-valvular atrial fibrillation rose considerably, doubling during
the study period. Furthermore, VKA prescription also increased,
leading to a staggering 30% increase in total OAC prescription.
NOAC initiation was associated with a lower baseline risk
of stroke and higher income. This opposes the indications
of NOAC use and reflects disparities in care, indicating the
need for a close monitoring of the appropriateness of OAC
prescription.
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